Acasti Pharma Inc (NASDAQ:ACST)

Acasti Pharma Inc (NASDAQ:ACST) Booms on Possible Deal

Acasti Pharma Inc (NASDAQ:ACST)

Acasti Pharma Inc (NASDAQ:ACST) stock was up over 155%, to $3.25, before retreating in the first 45 minutes of trading to the $2.25 handle for a 75%+ gain over Friday’s close of $1.27. Volume has been massive – almost 1,900 times the daily average. The move comes after the biopharmaceutical company announced entering into a non-binding, licensing term sheet with a leading China-based pharmaceutical company.

Acasti Pharma Inc (NASDAQ:ACST)

Acasti Pharma Inc (NASDAQ:ACST), headquartered in Quebec, Canada, is a biopharmaceutical company that is developing the cardiovascular drug, CaPre (omega-3 phospholipid), for the treatment of hypertriglyceridemia. This condition affects an estimated one third of the U.S. population. The company’s strategy is to initially develop and commercialize CaPre for the 3 to 4 million patients in the U.S. with severe hypertriglyceridemia.

Acasti Deal

At this stage, the licensing deal is non-binding. Upon its execution, the proposed term sheet expects that Acasti would receive an upfront payment of $8 million, additionally there would be regulatory and commercial milestone payments in excess of $125 million, and tiered double-digit royalties on net sales.

The deal grants an exclusive license to the Chinese pharmaceutical company to commercialize CaPre in China and other specified Asian countries. With the high prevalence of hypertriglyceridemia in Asia, this potential partnership presents a significant commercial opportunity for both Acasti Pharma Inc (NASDAQ:ACST) and CaPre.

Acasti’s press release specifies that the deal is not yet agreed to, and conditions and terms may change from those that have been released to the public.

ACST Stock Performance

Shares of Acasti Pharma Inc (NASDAQ:ACST) have been largely flat for the year, losing 5.2% prior to today’s price action. It has been trading in a range between $1.20 and $1.40 for most of 2016 and 2017, but briefly spiked to hit a 52-week high of $2.46.

In August, the company reported its Q1 2018 financial results. Its net loss was C(-$2.8) million or C(-$0.19) per share which was an improvement on its performance for the same period of the prior year when the loss was C(-$3.2) million or C(-$0.29) per share.

Acasti Pharma Inc (NASDAQ:ACST) has a low float figure of 8.1 million shares which makes it a favorite of momentum traders. ACST stock has a Relative Strength Index score of 90 which places it well into the metric’s range that most observers consider to be in “overbought” status.

ACST shares have a listed one-year target share price of $8.21.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ACST and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

CASI Pharmaceuticals Inc. (NASDAQ:CASI)

CASI Pharmaceuticals Inc. (NASDAQ:CASI) Reports Narrow Q3 Net Loss

CASI Pharmaceuticals Inc. (NASDAQ:CASI)

Shares of CASI Pharmaceuticals Inc. (NASDAQ:CASI) gained 8.37% after the biopharmaceutical company reported a narrower than expected net loss for the three and nine months ended September 30, 2017. In addition, the company was able to strengthen its balance sheet through the issuance of shares to certain investors.

CASI Pharmaceuticals Inc. (NASDAQ:CASI)

Declining Net Loss

Net loss for the third quarter came in at ($1.6) million or (-$0.03) a share, compared to a net loss of (-$1.7) million reported last year. For the first nine months of the year, CASI Pharmaceuticals net loss totaled (-$5.7) million, compared to a net loss of (-$6.8) million reported last year.

CASI Pharmaceuticals Inc. (NASDAQ:CASI) attributes the decline in net loss to a decrease in non-cash compensation expense associated with stock option issuance. Clinical expenses associated with the development of the company’s lead candidate drug ENMD-2076 were also down in the quarter.

“I am pleased with our third quarter financial results. In October, we announced a $23.8 million registered direct offering, funds raised from which will be used to advance our internal pipeline and support our business development in-license activities,” said CEO Ken K. Ren.

CASI Stock Performance

Investors reacted to the declining net loss by pushing the stock up the chart. The stock is currently trading in an uptrend as it makes a push for its 52-week high of $3.18 a share. CASI Pharmaceuticals is up by more than 100% for the year, as it continues to outperform the overall industry.

Data compiled by Zacks Investment Research indicates that the stock is currently rated as a ‘strong buy’ by one analyst firm. Analysts are forecasting a 14.71% year over year increase in earnings this year compared to last year. However, the analysts expect a -6.9% earnings growth next year.

Public Offering

Separately, China’s Food and Drug Administration has granted a priority review for CASI Pharmaceuticals Inc. (NASDAQ:CASI) clinical trial application for EVOMELA for injection. Depending on the review, the company could make a clinical trial application by the end of the year.

In September, CASI Pharmaceuticals Inc. (NASDAQ:CASI) entered into agreements with certain institutional and accredited investors for the purchase of approximately $23.8 million securities in a direct offering. The company expects net proceeds of $23.3 million that is to be used to support business development activities which includes advancing clinical trial programs.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CASI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Celsion Corporation (NASDAQ:CLSN) Q3 Results Disappoint

Celsion Corporation (NASDAQ:CLSN)

Shares of Celsion Corporation (NASDAQ:CLSN) fell 5.2% after the oncology drug development company reported financial results for the three and nine months ended September 30, 2017. A net loss for the two periods appears to have spooked the market, fuelling a sell-off of the stock.

Celsion Corporation (NASDAQ:CLSN)

CLSN Sell-Off

Following Tuesday’s sell-off, Celsion Corporation (NASDAQ:CLSN) is at risk of dropping to this year’s lows as it continues to trade in a strong downtrend. The stock has shed more than 50% in market value since the start of the year as investors continue to question the company’s long-term prospects.

However, data compiled by Zacks Investment Research indicates that two analyst firms currently rate the stock as a ‘strong buy’ amidst the growing short interest. Despite disappointing financial results, analysts are forecasting a 76.6% year over year increase in earnings. The analysts also expect earnings to grow by 48.4% next year.

For the quarter ended September 30, 2017, Celsion Corporation (NASDAQ:CLSN) reported a net loss of (-$5.7) million or (-$0.70) a share compared to a net loss of (-$6.4) million reported last year. The company attributes the decrease to a tighter clinical development focus coupled with lower operational expenses. Net loss for the first nine months came in at (-$16.1) million compared to (-$16.7) million as of last year.

Celsion Pipeline Development

During the quarter Celsion Corporation (NASDAQ:CLSN) recognized deemed dividends totaling $0.4 million with regards to multiple agreements with certain warrant holders. The company also made important milestones in the development of its lead clinical programs and capital infusion of $38 million to help drive the development efforts.

Celsion Corporation (NASDAQ:CLSN) is currently working on ThermoDox, its proprietary heat-activated liposomal encapsulation currently in Phase III for the treatment of primary liver cancer. The company’s immunotherapy program consisting of GEN-1 is currently in Phase 1 development as a localized treatment for Ovarian Cancer.

“We believe that we now have sufficient capital to complete enrollment of our Phase III OPTIMA Study and through the first efficacy analysis expected in the first quarter of 2019. Further, we expect that our current funds will allow us to make substantial progress in our open-label, randomized, 86 patient Phase I/II study of GEN-1 in newly diagnosed stage III and IV ovarian cancer patients,” said CEO, Michael Tardugno.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CLSN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

MoSys Inc. (NASDAQ:MOSY)

MoSys Inc. (NASDAQ:MOSY) Spikes

MoSys Inc. (NASDAQ:MOSY)

MoSys Inc. (NASDAQ:MOSY) shares have spiked over 140%, to $1.60, on the back of massive volumes after the technology company reported Q3 2017 financial results. Volume has been huge. Currently, over 127 times the average share volume has traded today.

MoSys Inc. (NASDAQ:MOSY)

MoSys, Inc. (NASDAQ:MOSY) is a nano-cap ($5.4 million) fabless semiconductor company enabling leading equipment manufacturers of Cloud, networking, communications, and data center systems to address the continual increase in Internet users, data and services. The company’s solutions deliver data path connectivity, speed and intelligence while eliminating data access bottlenecks on line cards and systems scaling from 100G to multi-terabits per second.

MoSys Q3 Earnings

MoSys, Inc. (NASDAQ:MOSY)’s Q3 2017 net loss was $1.7 million, or ($0.22) per share, compared with a net loss of $4.0 million, or ($0.60) per share, for the previous quarter and a net loss of $4.7 million, or ($0.71) per share, for the same period in 2016. Total net revenue for Q3 2017 was $2.5 million, compared with $1.4 million for the previous quarter and $1.6 million for the third quarter of 2016. Product revenue for the third quarter was $2.2 million, compared with $1.1 million in the second quarter of 2017 and $1.2 million in the year-ago period.

Len Perham, President and CEO of MoSys, Inc. (NASDAQ:MOSY), “Our revenue growth in the third quarter was primarily driven by increased shipments to our largest Bandwidth Engine 2 customers. More specifically, the design wins with our lead security-appliance customer entered production in early 2017, and have been a significant driver of our increased revenue this past year. As part of our close collaboration with our lead customers, we have developed a solid backlog that extends out through 2018.”

MOSY Stock Performance

The consensus of analysts gave shares of MoSys, Inc. (NASDAQ:MOSY) a one-year price target of $2.00. That level has not been reached since late June, after which MOSY shares began a slide that saw the shares trade under the important $1 level for the majority of the trading sessions since the beginning of September.

MOSY shares have drastically underperformed the sector and market over the past year. Year-to-date MOSY shares are down over 70%. Over the past month, shares have dropped over 20%. Despite the poor performance, today’s spike has moved MOSY’s Relative Strength Index score to 83 – a figure well above the threshold normally considered for labeling a stock as “overbought”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MOSY and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Biostar Pharmaceuticals Inc (NASDAQ:BSPM) Attempts a Close above $2

Biostar Pharmaceuticals Inc (NASDAQ:BSPM)

Biostar Pharmaceuticals Inc (NASDAQ:BSPM) stock is up over 20% and trading above a key $2 resistance level. Volume is heavy – nearly 30 times the listed daily average. No news has come out on the drug manufacturer, but observers are speculating that the market may be jumping in ahead of the company’s earnings release on November 20, 2017.

Biostar Pharmaceuticals Inc (NASDAQ:BSPM)

Biostar Pharmaceuticals Inc (NASDAQ:BSPM), headquartered in China, through its wholly owned subsidiary and controlled affiliates, develops, manufactures, and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company’s most popular product is its XinAoxingOleanolic Acid Capsule, an over-the-counter medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population.

Biostar’s Business

The company has a current ratio of 1.3, which indicates it will be able to satisfy any debt obligations in the near term. While its cash/share figure is only $0.07, it has a book/share value of $14.43. According to reports, industry analysts are expecting Biostar Pharmaceuticals Inc (NASDAQ:BSPM) earnings to grow almost 80% this year.

Sales have taken a hit since 2014 when the company posted a figure of $61.4 million. That year represented the end of an uptrend in its sales. In 2015 the company reported sales of $27.1 million, and just $2.4 million for 2016.

BSPM Stock Performance

Over the past year, BSPM has lost over 50% of its value. In 2016, the stock struggled to remain over the $5 handle and any gains over that price quickly met with selling action. However, in the past quarter BSPM stock has gained around 20%. Further, analysts have a consensus, one-year price target of $7 on the shares. Currently, BSPM stock is trading 70% above its 52-week low of $1.18, but well below its 52-week high of $4.30.

Earnings have been disappointing for long-term holders of the shares. In 2015, the company posted a per share loss of ($11.36, but last year that shrank to (-$2.48). Dilution has been noticeable, but not cringe-worthy. In 2013 there were 1.37 million shares outstanding. But by 2016 the number was listed at 2.3 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $BSPM and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)’s Posts Unexpected Net Loss

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)

Shares of AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) fell 5.13% in after-hours trading on Thursday as investors reacted to the company’s Q3 financial results. A wider than expected net loss for the three and nine months ended September 30, 2017, appears to have spooked investors and fueled a sell-off of the stock.

DSUVIA NDA Woes

Investor confidence on the stock has hit an all-time low in the wake of the U.S. Food and Drug Administration issuing a Complete Response Letter to the company’s new drug, Dsuvia. The stock plunged to a new 52-week low of $1.95 after the regulator rejected a New Drug Application (NDA) for the drug, pending submission of additional safety data.

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) has shed more than 60% in market value over the past one month as investors remain skeptical about Dsuvia prospects following the FDA verdict. Disappointing Q3 financial results could accelerate the stock’s sell-off given that the company has no approved products in the market. Its growth is mostly pegged on the success of its opioid analgesics pipeline which under development.

The specialty Pharmaceutical Company has submitted an application for a Type A meeting with the FDA. The meeting is to be used to shed more light on all the requirements that the company must meet as it eyes DSUVIA NDA resubmission.

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) has already filed a marketing authorization application in Europe.

“DSUVIA remains our core asset as we believe the recommendations in the CRL are manageable. In addition, we successfully completed the ZALVISO Phase 3 study requested by the FDA, and remain focused on providing physicians and patients with non-invasive pain management options for moderate-to-severe acute pain within medically supervised settings,” said CEO, Vince Angotti.

AcelRx Q3 Financial Results

For the three months ended September 30, 2017, AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) generated a net loss of (-$13) million or (-$0.28) a share, compared to a net loss of (-$11.4) million generated last year. Net loss from operations totaled (-$8.9) million compared to (-$8) million during the third quarter of last year. Net Loss for the first nine months of the year increased to (-$41.4) million from (-$33.5) million as of last year.

Revenue in the quarter totaled $1.5 million made up of $1.2 million related to a collaboration with Grunenthal. Revenue for the nine months ended September 30, 2017, totaled $7.2 million. R&D and G&A expenses for the third quarter totaled $8.3 million and $28.4 million for the nine months ended September 30, 2017.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ACRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Genocea Biosciences Inc. (NASDAQ:GNCA)

Investor Confidence in Genocea Biosciences Inc. (NASDAQ:GNCA) Drops

Genocea Biosciences Inc. (NASDAQ:GNCA)

Investor confidence in Genocea Biosciences Inc. (NASDAQ:GNCA) has taken a hit in the wake of disappointing third quarter financial results. Shares of the company fell 12.6% in Tuesday’s trading session as law firms alleged possible securities violations following the earnings report.

Genocea Biosciences Inc. (NASDAQ:GNCA)

Class Action Investigation

A wider than expected net loss for the quarter appears to have spooked investors, accelerating a sell-off that began in May. The stock has shed more than 70% of its total market value since the start of the year as it continues to trade in a strong downtrend.

The stock’s sentiments have also taken a hit from law firms that allege the company provided materially false and misleading statements regarding business operation and compliance policies. According to Pomerantz LLP, the biopharmaceutical company failed to disclose its funds were insufficient to support Phase 3 trials of GEN-03.

Genocea Biosciences Inc. (NASDAQ:GNCA) is also accused of overstating the potential of its lead candidate drug GEN-003. In September, the company was forced to halt spending and development activities of the drug as it explored strategic alternatives. The news caused the stock to drop 76.5% to close at $1.25 a share.

Q3 Financial Results

In addition to the class action lawsuit, a Q3 net loss of (-$16.9) million compared to a net loss of (-$12.8) million reported last year has not gone well with investors. Research and development expenses in the quarter increased $1.3 million to $1.2 million. The company attributes the increase to higher external manufacturing related expenses and increase in compensation to support Phase development of GEN-003.

During the third quarter, Genocea Biosciences Inc. (NASDAQ:GNCA) implemented a corporate restructuring that resulted in a strategic shift to immuno-oncology. The changes resulted in a charge of $1.1 million to be paid in the fourth quarter. The company exited the quarter with cash and cash equivalent of $22 million compared to $35.2 million at the end of the second quarter. The existing finances are sufficient to support operating expenses and capital expenditure into the middle of 2018.

Separately, Genocea Biosciences Inc. (NASDAQ:GNCA) is to highlight the power of its proprietary antigen identification system ATLAS at the upcoming Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

“These data demonstrate the versatility of ATLAS and support our use of the technology in the development of next-generation neoantigen cancer vaccines,” said Jessica Baker Flechtner, Ph.D., chief scientific officer at Genocea.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $GNCA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

NASDAQ:ONCS

Is OncoSec Medical Inc. (NASDAQ:ONCS) A Buy?

OncoSec Medical Inc. (NASDAQ:ONCS)

Shares of OncoSec Medical Inc. (NASDAQ:ONCS) traded lower following the posting of better than expected fourth quarter and full year financial results. The stock was down by 3.79% in Monday’s trading session, to end the day at $1.27 a share.

OncoSec Medical Inc. (NASDAQ:ONCS)

ONCS Stock Performance

OncoSec Medical Inc. (NASDAQ:ONCS) has gained more than 30% in market value over the past month. The impressive run has seen the stock trade above January’s trading levels after erasing a good chunk of losses accrued for the better part of the year. The stock faces immediate resistance at the $1.30 mark, above which it could make a push for the $1.52 mark.

Renewed investor interest in the stock follows the announcement that the company has made significant progress in the development of its lead clinical program ImmunoPulse IL-12. The company is developing the program for the treatment of metastatic melanoma.

During the fourth quarter, the biotechnology company presented positive Phase 2 data of ImmunoPulse IL-12, in combination with pembrolizumab.

“Our organization remains focused on advancing our PISCES/KEYNOTE-695 registration-directed trial to address this significant unmet medical need through an innovative accelerated pathway,” said CEO, Punit Dhillon.

OncoSec Q4 Financial Results

In addition to progress on the clinical development front, OncoSec Medical Inc. (NASDAQ:ONCS) is also working on trimming its net loss as it eyes positive cash flow. For the three months ended July 31, 2017, the company generated a net loss of (-$5.8) million, down from (-$6.6) million reported last year. Net loss for the full year dropped to ($21.4) million from ($26.9) million.

OncoSec Medical Inc. (NASDAQ:ONCS) attributes the decrease in net loss to a $2.2 million decrease in non-cash, stock-based compensation expense and a $1.8 million decrease in Research and Development Expense. The company did not generate any revenue in the fourth quarter and full year.

The biotechnology company exited the fourth quarter with $11.4 million in cash and cash equivalent, down from $28.7 million as of July 31, 2016. The funds should finance the company’s operations through the third quarter of FY2018.

Last Month OncoSec Medical Inc. (NASDAQ:ONCS) closed a $7.1 million direct offering of 5.3 million shares of common stock, priced at $1.34 a share. The company also issued warrants for the purchase of additional shares at an exercise price of $1.25 a share.

OncoSec intends to use net proceeds of about $6.2 million for working capital and general corporate purposes such as the PISCES/KEYNOTE-695 study, among other clinical, research and development activities.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ONCS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Phase 2 Data Boosts Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) have hit $6.35 (up over 70%) in pre-market trading on heavy volumes. The Canadian-based company released top-line results from its Phase 2b AURA-LV (AURA) study in lupus nephritis with the firm’s product candidate voclosporin.

Lupus nephritis is a type of kidney disease. The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus. Lupus is much more common in women than in men and most often strikes during the child-bearing years. Nine out of ten people who have lupus are women and is found more frequently in people of African or Asian background. African Americans and Asian Americans are about 2 to 3 times more likely to develop lupus than Caucasians.

At 48 weeks, the trial met the complete and partial remission endpoints, demonstrating statistically significantly greater complete and partial endpoints in patients in both low dose and high dose cohorts versus the control group. No unexpected safety signals were observed and there were no additional deaths in the voclosporin treated patients; however, there were three deaths and one malignancy reported in the control arm after completion of the study treatment period. Three deaths occurred during the trail but, according to reports, all were in the placebo group of the trial.

Dr. Brad Rovin, FASN, Director of Nephrology and Vice Chairman of Research for the Department of Internal Medicine at the Ohio State University Wexner Medical Center stated in a press release “The AURA trial’s long-term results convincingly demonstrate that the addition of voclosporin to standard of care treatment is superior to standard of care alone. These data are not only statistically significant, but clinically important. Twice as many patients given 23.7mg voclosporin twice daily achieved a complete renal response compared to those treated with placebo.”

Prior to today’s market activity, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) had impressive performance. AUPHG shares were up 77.5% for the year, 76.7% YTD, and 15.94% for the month. Should AUPH hold these price levels, it will close the day with new 52-week closing highs. Five firms follow Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH). Four rate AUPH shares as a “Strong Buy” and one rates the shares as a “Hold”.

3/2/2017
Ticker Symbol AUPH
Last Price a/o 9:00 AM EST  $                      6.18
Average Volume                1,750,000
Market Cap (mlns)  $                  143.93
Sales (mlns) $0.20
Shares Outstanding (mlns) 38.79
Share Float (mlns) 22.43
Shortable Yes
Optionable Yes
Inside Ownership 0.00%
Short Float 11.73%
Short Interest Ratio 1.5
Quarterly Return 23.67%
YTD Return 76.67%
Year Return 77.51%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy. 

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading.

Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) Deal with Valeant (VRX) Has Investors in Tears of Joy

Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG)

Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) had a market cap of $16 million when traders woke up this morning. Then the biotechnology firm announced a world-wide licensing agreement with $5.5 billion Valeant Pharmaceuticals International (NYSE:VRX) and by early afternoon Eyegate’s market cap had increased to almost $30 million. Even more eye-popping are the volumes being traded. EYEG is trading at over 75 times their average daily volumes.

Waltham, MA-based Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) an exclusive, worldwide licensing agreement with Valeant Pharmaceuticals International (NYSE:VRX) through which EyeGate has granted a subsidiary of Valeant exclusive, worldwide commercial and manufacturing rights to the EyeGate® II Delivery System and EGP-437 combination product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients. Under the license agreement, EyeGate received an upfront cash payment and has the potential to receive certain development-based milestone payments, as well as additional milestone payments based on the achievement of certain cumulative and annual sales milestones. Additionally, EyeGate will receive royalties on Valeant’s net sales of the product.

EGP-437 was Eyegate’s first product candidate. A similar licensing deal had been in place with Valeant for the EyeGate® II Delivery System and EGP-437 combination product candidate that had already yielded milestone payments Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG). That deal, however, was for the treatment of uveitis – the current deal addresses a much larger market.

Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) has one other product candidate in its pipeline – an “ocular bandage gel” (OBG) for patients that have undergone a photorefractive keratectomy. At the end of January, the company announced that the study demonstrated safety and tolerability of EyeGate OBG, with encouraging potential efficacy. 75% of the subjects in Arm 1 (EyeGate OBG alone) achieved complete wound closure by Day 3, compared to 53.8% of patients that received the standard of care. Additionally, the average wound surface area on Day 1 (24 hours post-surgery) was 18.5 mm2 for patients in the EyeGate OBG alone arm compared to 39.5mm2 in the BCL arm, a 53.3% improvement. Based on these positive results, Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) plans to continue development with a double-masked, controlled trial evaluating EyeGate OBG monotherapy against BCL in Q2 2017.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Marc has a degree in economics and a MSc. in Finance. Over his 20 year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

2/21/2017
Ticker Symbol EYEG
Last Price a/o 1:26 PM EST  $                      3.07
Average Volume                    335,900
Market Cap (mlns)  $                    15.90
Sales (mlns) $0.50
Shares Outstanding (mlns) 9.7
Share Float (mlns) 9.11
Shortable Yes
Optionable No
Inside Ownership 3.90%
Short Float 2.89%
Short Interest Ratio 0.78
Quarterly Return 12.32%
YTD Return 0.61%
Year Return -44.22%